Getting closer. 750k in funding from private investor announced for moving brain cancer study along. They have gone above and beyond to keep costs low and not take any loans.
data on COVID coming from Boris Shor at Manhattan BioSolutions and Syracuse University.
Brain cancer study:
SAN DIEGO, CA / ACCESSWIRE / August 24, 2020 / Nascent Biotech, Inc (OTCQB:NBIO) announced today that it is closing on a direct private placement with aggregate proceeds of $740,000.
The proceeds allow the Company to complete the required testing for removing the partial clinical trial hold, imposed by the FDA, and will permit the company to begin the Phase I clinical trials on brain cancer.
Sean Carrick, CEO of Nascent commented, "The financing has come from private individual investors and we are pleased by the interest in this round. We chose to accept strategic money knowing equity funding will prove to be more beneficial to the Company than debt financing."
About Nascent Biotech, Inc.:
Nascent Biotech, Inc. is a clinical-stage biotech company pioneering the development of monoclonal antibodies (mAbs) for the treatment of incurable cancers such as brain and pancreas, as well as hard-to-treat cancers such as colon and lung. Nascent is also employing its mAbs as part of treatments for dangerous viral infections, such as COVID-19. Collectively, cancers and viral infections afflict and kill tens of millions worldwide each year. Nascent's products are not commercially available. Our lead candidate, Pritumumab (PTB), is a fully human mAb that will commence study in an FDA-approved Phase I clinical trial later this year for the treatment of primary and metastatic brain cancer, including glioblastoma and malignant astrocytoma. Development of PTB as a potential treatment for COVID-19 has been initiated. For more information, visit www.nascenbiotech.com.
News 
Market Data 
Discover 
